Newsgroup: it.economia.borsa.estero
Titolo: SNVBF...??

 Let me tell you about a biotech firm with several breakthrough discoveries.
One is a SARS vaccine.
     After new cases of SARS were confirmed earlier this year, it appears
that this infectious disease is threatening the global population once
again.
     But this time, scientists at Sinovac have a head start. After nine
months of research and development, they recently received approval to
conduct the very first human clinical trials for the SARS vaccine. Their
next goal is to roll out the first-ever vaccine for the disease, a move that
could deliver double or triple profits to early investors.
     If you're ready to profit, here's what you need to know. . .
Richard Scmidt
Homerun Stock Alert
Investor,
     An exciting new biotech stock recently showed up on my radar, and since
it promises to become one of my biggest winners yet, I wanted to tell you
about it immediately.
     As a publicly traded U.S. company, Sinovac Biotech Ltd. has the
potential to successfully tap the worldwide vaccine market for several of
the world's most widespread diseases. And while the risk level is high, so
is the upside potential.
COMPANY OVERVIEW
     With every new infectious disease that shows up on the world scene,
whether it's SARS or an exotic strain of influenza, the demand for human
vaccines grows by leaps and bounds. For this reason, Sinovac is becoming
more and more attractive to investors who are looking for an aggressive
stock that can provide them with hefty returns.
     Based in Beijing, China, Sinovac has quietly carved out a name for
itself by focusing on the research, development and commercialization of
human vaccines. As a result, the company is already at the forefront of the
Chinese vaccine market and is expanding internationally as well.
     In the global race to create a safe and effective vaccine for SARS,
Sinovac is at least a year ahead of the competition. What's more, the market
potential of the vaccine is enormous since the disease can infect people of
all ages, anywhere in the world.
     The company has already successfully launched HealiveT, its hepatitis A
vaccine, in 2002. In fact, the vaccine sold an estimated 450,000 units for
about USD $7 per unit in its first full year of production. According to the
Sinovac management team, strong sales should continue through at least the
next five years.
     Sinovac also has several other proprietary vaccines in the pipeline,
including an influenza vaccine as well as a combination hepatitis A & B
vaccine.
RECOMMENDATION
     Since this is my #1 biotech stock recommendation for aggressive
investors in 2004, I strongly urge you to learn more about Sinovac by
visiting 
http://www.breakthroughstock.com/
. While there, you can also find
out how to regularly receive other Homerun Stock Alert recommendations like
this.
     Mark my words: Keep following my recommendations on this rising star
and in 18 months or less, your $5,000 investment could easily turn into
$10,000!
     To invest in Sinovac Biotech, Ltd. (OTCBB: SNVBF) now, go online or
contact your discount broker.
Richard Schmidt
Homerun Stock Alert
      Name of stock: Sinovac Biotech Co., Ltd.
      Symbol: OTCBB: SNVBF
      Low projection: $5.50
      High projection: $8.25
      RECOMMENDATION: STRONG BUY

Titolo per pochi eletti.....
non saranno molti quelli che possono operare all'OTC

con Directa si può ho controllato ora...;-)>

 con Directa si può ho controllato ora...;-)>
Insomma mi volete proprio far cambiare TOL!
aspetto ancora stop loss e short,
poi mi trasferisco su Directa :)

ne ho prese un po' le tengo li...
certo però che ora dovrei diventare un po' sadico....:-DDD